Ambassadeur de la Health Valley : AC Immune signe un deal à CHF 80M upfront avec Lilly

Ambassadeur de la Health Valley : AC Immune signe un deal à CHF 80M upfront avec Lilly

AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE:LLY) announced that the two companies have signed a license and collaboration agreement that will focus primarily on AC Immune’s lead molecule, ACI-3024, which has demonstrated tau aggregation inhibition in preclinical models. Under the terms of the agreement, AC Immune will receive an upfront payment of CHF80 million as well $50 million in exchange for a note, convertible to equity at a premium. AC Immune is also eligible to receive CHF60 million in potential near-term development milestones, as well as other potential development, regulatory and commercial milestones up to approximately CHF1.7 billion, and tiered royalty payments in the low double digits.

MORE

Leave a reply